Keryx Biopharmaceuticals Inc
KERX
KERX was delisted on the 12th of December, 2018.
124 hedge funds and large institutions have $660M invested in Keryx Biopharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 31 funds opening new positions, 38 increasing their positions, 42 reducing their positions, and 16 closing their positions.
94% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 16
32% more call options, than puts
Call options by funds: $32.7M | Put options by funds: $24.7M
30% more capital invested
Capital invested by funds: $508M → $660M (+$151M)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
13% more funds holding
Funds holding: 110 → 124 (+14)
10% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 42
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$32.9M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.4M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$19.4M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
+$15.5M |
| 5 |
ACM
Apex Capital Management
Dayton,
Ohio
|
+$9.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DM
Deerfield Management
New York
|
-$28.3M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$24.1M |
| 3 |
JP Morgan Chase
New York
|
-$21.8M |
| 4 |
VM
VHCP Management
New York
|
-$12.5M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$11.2M |
KERX Hedge Fund Activity: Q4 2013 in Review
124 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Keryx Biopharmaceuticals Inc (KERX) for Q4 2013, worth a combined $660M — up 30% from $508M a quarter earlier.
Buyers outnumbered sellers: 31 funds opened new KERX positions and 16 closed out — a net gain of 15 holders — while 38 added to existing stakes and 42 trimmed.
The largest buyer was Sectoral Asset Management, opening a new position worth an estimated $32.9M. The largest seller was Deerfield Management, cutting an estimated $28.3M.
- 124 institutional investors held Keryx Biopharmaceuticals Inc (KERX) as of Q4 2013, up from 110 in Q3 2013.
- Funds reported $660M of Keryx Biopharmaceuticals Inc stock for Q4 2013, up 30% quarter-over-quarter.
- 31 funds opened new Keryx Biopharmaceuticals Inc positions in Q4 2013 and 16 closed out, a net change of +15 holders.
- The largest Keryx Biopharmaceuticals Inc buyer in Q4 2013 was Sectoral Asset Management, an estimated $32.9M added.
- The largest Keryx Biopharmaceuticals Inc seller in Q4 2013 was Deerfield Management, an estimated $28.3M sold.
Based on aggregated 13F filings for Q4 2013.